+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bronchial Spasms Treatment Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Bronchial Spasms Treatment Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Bronchial Spasms Treatment Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011461
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bronchial Spasms Treatment Market grew from USD 309.72 million in 2024 to USD 323.86 million in 2025. It is expected to continue growing at a CAGR of 4.39%, reaching USD 400.96 million by 2030.

Bronchial spasms remain a critical challenge for clinicians and patients alike, manifesting as sudden constrictions of the airway muscles that trigger coughing, wheezing, and breathlessness. This executive summary examines the multifaceted treatment landscape, spotlighting the driving forces reshaping care protocols and therapeutic innovation. It opens with an overview of emerging scientific insights and evolving patient needs, setting the stage for a deeper exploration of how regulatory shifts, tariff adjustments, and evolving reimbursement scenarios influence treatment access and outcomes. By focusing on the most impactful trends and translating complex data into actionable intelligence, decision-makers will gain clarity on strategic imperatives and growth opportunities. The narrative balances rigorous analysis with concise takeaways, ensuring both clinical experts and industry leaders can navigate the landscape with confidence. As the healthcare community seeks to optimize outcomes for individuals living with bronchial spasms, understanding these dynamics is essential to forging pathways toward improved patient quality of life and sustainable organizational performance.

Transformative Shifts in the Treatment Landscape

Over the past decade, several transformative shifts have redefined how bronchial spasms are treated. Advances in precision medicine have enabled tailored pharmacologic regimens, moving beyond one-size-fits-all approaches. At the same time, digital health solutions-such as remote spirometry monitors and telehealth consultations-have empowered patients to manage acute episodes and maintenance therapy from home, improving adherence and reducing hospital readmissions. Additionally, novel biologic agents targeting specific inflammatory pathways are gaining traction, challenging traditional reliance on broad-spectrum bronchodilators. Integration of complementary modalities, including acupuncture and herbal remedies supported by rigorous clinical trials, further diversifies the therapeutic arsenal. Finally, cross-disciplinary collaborations between pulmonologists, physiotherapists, and primary care providers strengthen coordinated care models, ensuring interventions align with patient-specific risk factors and lifestyle considerations. These shifts collectively accelerate progress toward more effective, personalized management of bronchial hyperreactivity.

Cumulative Impact of United States Tariffs in 2025

Recent tariff revisions enacted by U.S. authorities in 2025 have introduced wider duties on imported medical devices and pharmaceutical ingredients critical to bronchial spasm management. These cumulative policy adjustments have elevated input costs for inhalation devices, injectables, and specialized thermoplasty equipment, prompting manufacturers to reconsider supply chains and procurement strategies. As a result, some producers have localized manufacturing activities to Latin America and the Asia-Pacific region to mitigate elevated duties and currency volatility. Meanwhile, healthcare providers face increased negotiation complexity with distributors, impacting contract pricing and reimbursement negotiations. Despite these headwinds, several companies have secured tariff exemptions for high-priority biologics and diagnostic tools by demonstrating domestic research collaborations. Moving forward, stakeholders must proactively engage with policymakers to balance trade protection goals with the imperative to ensure patient access to life-saving therapies.

Key Segmentation Insights Across Treatment Modalities and Patient Profiles

Dissecting the bronchial spasms treatment spectrum through multiple lenses reveals nuanced patterns of adoption and unmet need. Based on treatment type, options span alternative therapies such as acupuncture, chiropractic care, and herbal remedies; conventional medications including anticholinergics, bronchodilators, and methylxanthines; physiotherapy techniques; and advanced surgical interventions like bronchial thermoplasty and lung volume reduction surgery. Patient demographics further stratify demand, with differentiated care protocols for adult, pediatric, and geriatric populations, tailored approaches for male and female patients, and specialized counseling for smokers and non-smokers to address lifestyle-driven risk factors. The healthcare environment classification highlights varying utilization rates in homecare, inpatient facilities, and outpatient clinics, each with distinct training and resource requirements. Emergency treatment versus maintenance management shapes device design and supply chain logistics. Severity level segmentation underscores the shift from mild condition monitoring to intensive protocols for severe cases. Delivery modalities emphasize inhalation formats-including dry powder and metered-dose inhalers-injectable routes via intravenous or subcutaneous administration, and oral formulations. End-use settings range from primary care clinics to homecare environments and hospital systems. Finally, reimbursement scenarios span out-of-pocket payment, private insurance coverage, and public funding, while clinical settings from emergency rooms to specialty clinics influence treatment pathways and protocol standardization.

Key Regional Insights Impacting Access and Adoption

Regional dynamics play a pivotal role in shaping access, regulatory compliance, and patient preferences. The Americas continue to invest heavily in digital health infrastructure, with widespread adoption of telemonitoring devices in community settings and progressive reimbursement frameworks that support at-home care. In contrast, Europe, Middle East & Africa exhibit heterogeneity driven by divergent national regulations and varying rates of public health insurance coverage, fostering opportunities for private-public partnerships to facilitate broad-based screening and preventive programs. The Asia-Pacific region demonstrates rapid uptake of alternative therapies and cost-effective generics, underpinned by growing middle-class demand and expanding pharmaceutical manufacturing capacity. Cross-regional collaborations, such as joint research consortia and shared regulatory harmonization efforts, further smooth pathways for launching innovative biologics and device-based solutions globally.

Key Company Insights and Strategic Positioning

A competitive landscape featuring established global leaders and agile specialized firms defines bronchial spasm therapies. Amphastar Pharmaceuticals, Inc has expanded its inhalation device portfolio to integrate digital adherence monitoring. Bayer AG leverages its broad respiratory pipeline to advance novel biologics targeting airway inflammation. C.H. Boehringer Sohn AG & Co. KG emphasizes strategic alliances with academic centers to accelerate translational research. CHIESI Farmaceutici S.p.A. focuses on patient-centric device ergonomics. Cipla Limited drives affordability through efficient manufacturing corridors. GlaxoSmithKline plc continues to refine its combination therapies. Grifols, S.A. advances plasma-derived solutions aimed at immune modulation. Lybrate, Inc. pioneers telehealth integration for acute episode management. Merck KGaA collaborates on next-generation bronchodilators. Novartis AG explores gene therapy approaches for refractory cases. Orion Corporation enhances its respiratory diagnostics toolkit. Pfizer Inc invests in long-acting injectables. Temple University Health System, Inc. contributes real-world evidence to refine clinical guidelines. Teva Pharmaceutical Industries Ltd scales production of generic inhalation platforms. Vectura Group Ltd by Philip Morris International Inc. develops novel inhaled particle technologies. Viatris Inc. orchestrates global distribution networks to ensure continuity of care across diverse markets.

Actionable Recommendations for Industry Leaders

Industry leaders should pursue a series of targeted actions to sustain competitive advantage and expand patient reach. First, optimizing supply chains through regional manufacturing alliances and near-shoring can shield operations from tariff volatility and logistics disruptions. Second, investing in digital therapeutics and remote monitoring platforms will enhance patient engagement, support adherence, and generate real-world data to inform clinical improvements. Third, forging cross-sector partnerships between device manufacturers, pharmaceutical firms, and telehealth providers will accelerate integrated care models that span acute and maintenance phases. Fourth, engaging proactively with regulators to secure expedited approvals and tariff relief for innovative biologics and devices will streamline market entry. Fifth, embedding patient feedback loops into product design will ensure treatments address quality-of-life metrics alongside clinical efficacy. Finally, tailoring reimbursement strategies through evidence dossiers that underscore cost-offset benefits and long-term health outcomes will facilitate favorable coverage determinations across payers.

Conclusion: Navigating a Complex, Evolving Treatment Environment

Bronchial spasms treatment is undergoing a period of dynamic transformation driven by scientific advancements, policy shifts, and evolving patient expectations. As stakeholders navigate rising trade barriers, intricate segmentation profiles, and regional disparities, adaptability and collaboration emerge as decisive success factors. By aligning strategic investments with emerging therapy paradigms-ranging from precision biologics to telehealth-enabled care-organizations can deliver superior outcomes while optimizing resource allocation. Embracing an integrated approach that combines pharmacologic, device-based, and complementary modalities will address the full spectrum of patient needs, from mild episodes to severe, chronic conditions. Ultimately, the capacity to translate insights into scalable solutions will define leadership in this domain and elevate standards of compassionate, evidence-driven care across global healthcare ecosystems.

Market Segmentation & Coverage

This research report categorizes the Bronchial Spasms Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Alternative Therapies
    • Acupuncture
    • Chiropractic Care
    • Herbal Remedies
  • Medications
    • Anticholinergics
    • Bronchodilators
    • Methylxanthines
  • Physiotherapy
  • Surgery
    • Bronchial Thermoplasty
    • Lung Volume Reduction Surgery
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
  • Lifestyle
    • Non-smokers
    • Smokers
  • Homecare
  • Inpatient Care
  • Outpatient Care
  • Emergency Treatment
  • Maintenance Treatment
  • Mild
  • Moderate
  • Severe
  • Inhalation
    • Dry Powder Inhalers
    • Metered-dose Inhalers
  • Injectables
    • Intravenous
    • Subcutaneous
  • Oral
  • Clinics
  • Homecare Settings
  • Hospitals
  • Out-of-pocket
  • Private Health Insurance
  • Public Health Insurance
  • Emergency Rooms
  • Primary Care
  • Specialty Clinics

This research report categorizes the Bronchial Spasms Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bronchial Spasms Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Amphastar Pharmaceuticals, Inc
  • Bayer AG
  • C.H. Boehringer Sohn AG & Co. KG
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols, S.A.
  • Lybrate, Inc.
  • Merck KGaA
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc
  • Temple University Health System, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group Ltd by Philip Morris International Inc.
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bronchial Spasms Treatment Market, by Treatment Type
8.1. Introduction
8.2. Alternative Therapies
8.2.1. Acupuncture
8.2.2. Chiropractic Care
8.2.3. Herbal Remedies
8.3. Medications
8.3.1. Anticholinergics
8.3.2. Bronchodilators
8.3.3. Methylxanthines
8.4. Physiotherapy
8.5. Surgery
8.5.1. Bronchial Thermoplasty
8.5.2. Lung Volume Reduction Surgery
9. Bronchial Spasms Treatment Market, by Patient Demographics
9.1. Introduction
9.2. Age Group
9.2.1. Adult
9.2.2. Geriatric
9.2.3. Pediatric
9.3. Gender
9.3.1. Female
9.3.2. Male
9.4. Lifestyle
9.4.1. Non-smokers
9.4.2. Smokers
10. Bronchial Spasms Treatment Market, by Healthcare Environment
10.1. Introduction
10.2. Homecare
10.3. Inpatient Care
10.4. Outpatient Care
11. Bronchial Spasms Treatment Market, by Application Type
11.1. Introduction
11.2. Emergency Treatment
11.3. Maintenance Treatment
12. Bronchial Spasms Treatment Market, by Severity Level
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Bronchial Spasms Treatment Market, by Delivery Method
13.1. Introduction
13.2. Inhalation
13.2.1. Dry Powder Inhalers
13.2.2. Metered-dose Inhalers
13.3. Injectables
13.3.1. Intravenous
13.3.2. Subcutaneous
13.4. Oral
14. Bronchial Spasms Treatment Market, by End Use
14.1. Introduction
14.2. Clinics
14.3. Homecare Settings
14.4. Hospitals
15. Bronchial Spasms Treatment Market, by Reimbursement Scenario
15.1. Introduction
15.2. Out-of-pocket
15.3. Private Health Insurance
15.4. Public Health Insurance
16. Bronchial Spasms Treatment Market, by Clinical Setting
16.1. Introduction
16.2. Emergency Rooms
16.3. Primary Care
16.4. Specialty Clinics
17. Americas Bronchial Spasms Treatment Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Bronchial Spasms Treatment Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Bronchial Spasms Treatment Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Amphastar Pharmaceuticals, Inc
20.3.2. Bayer AG
20.3.3. C.H. Boehringer Sohn AG & Co. KG
20.3.4. CHIESI Farmaceutici S.p.A.
20.3.5. Cipla Limited
20.3.6. GlaxoSmithKline plc
20.3.7. Grifols, S.A.
20.3.8. Lybrate, Inc.
20.3.9. Merck KGaA
20.3.10. Novartis AG
20.3.11. Orion Corporation
20.3.12. Pfizer Inc
20.3.13. Temple University Health System, Inc.
20.3.14. Teva Pharmaceutical Industries Ltd
20.3.15. Vectura Group Ltd by Philip Morris International Inc.
20.3.16. Viatris Inc.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. BRONCHIAL SPASMS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BRONCHIAL SPASMS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BRONCHIAL SPASMS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CHIROPRACTIC CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HERBAL REMEDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHIAL THERMOPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-SMOKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SMOKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY EMERGENCY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MAINTENANCE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PUBLIC HEALTH INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY EMERGENCY ROOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PRIMARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 121. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 124. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 125. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 128. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 129. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 130. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 131. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 132. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 133. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 134. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 135. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 136. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 137. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 208. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 210. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 211. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 212. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 213. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 215. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 216. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 217. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 218. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 219. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 220. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 221. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 222. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 223. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 224. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 225. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 227. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 228. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 229. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 230. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 232. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 233. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 234. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 235. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 236. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 237. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 238. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 239. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 240. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 241. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 269. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 270. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 271. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY APPLICATION TYPE, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LIFESTYLE, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE BRONCHIAL SPASMS TREATMENT

Companies Mentioned

  • Amphastar Pharmaceuticals, Inc
  • Bayer AG
  • C.H. Boehringer Sohn AG & Co. KG
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols, S.A.
  • Lybrate, Inc.
  • Merck KGaA
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc
  • Temple University Health System, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group Ltd by Philip Morris International Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bronchial Spasms - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchial Spasms - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Bronchial Dysplasia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchial Dysplasia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Eprazinone Market by Indication, Product, Distribution Channel, Mode of Administation - Global Forecast 2025-2030 - Product Image

Eprazinone Market by Indication, Product, Distribution Channel, Mode of Administation - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Bronchitis Treatment Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Bronchitis Treatment Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease, Market Report, Forecast by Types, Treatment Types, Distribution Channels, Countries and Company Analysis, 2024-2032 - Product Image

Chronic Obstructive Pulmonary Disease, Market Report, Forecast by Types, Treatment Types, Distribution Channels, Countries and Company Analysis, 2024-2032

  • Report
  • 200 Pages
  • Global
From

About the Bronchial Spasm Drug Market

The Bronchial Spasm Drug market is a subset of the larger Respiratory Drugs market. Bronchial Spasm Drugs are used to treat bronchospasm, a condition in which the airways of the lungs become constricted, making it difficult to breathe. These drugs are typically administered through inhalation, and can be used to treat both acute and chronic bronchospasm. Commonly prescribed Bronchial Spasm Drugs include short-acting beta-agonists, long-acting beta-agonists, anticholinergics, and theophylline. The Bronchial Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Boehringer Ingelheim, Novartis, Sanofi, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.